Medicus Pharma Ltd. Common Stock

Medicus Pharma Ltd. Common Stock

MDCX - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$1.48M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Medicus Pharma Ltd. Common StockMedicus Pharma Ltd. Common Stock0-364%--
$1.00

Target Price by Analysts

11.9% downsideMedicus Pharma Ltd. Common Stock Target Price DetailsTarget Price
$0.27

Current Fair Value

76% downside

Overvalued by 76% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$1.48 Million
Enterprise Value$-3,431,789.00
Earnings per Share$-98
Beta-0.61
Outstanding Shares1,304,000

Return

Return on Equity363.97%ROE
Return on Assets-263.81%
Return on Invested Capital-578.03%

Valuation & Multiples

P/E Ratio-0.03P/E Ratio
PEG0.66PEG
Price to Sales-Price to Sales
Price to Book Ratio-0.13Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT0.08
Enterprise Value to Net Income0
Total Debt to Enterprise-0.05
Debt to Equity-0.01Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 13, 2026
EPS Estimate
-$6.68
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Next Earnings Call

Expected Date
March 24, 2027
EPS Estimate
-$5.50
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.00000%
Total Calls-
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %5.69%▲ 0.93%
Total Invested$504,670▼ 57.23%
Investors Holding23▲ 1.00%

About Medicus Pharma Ltd. Common Stock

16 employees
CEO: Raza Bokhari

Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company ...

Questions & Answers